Literature DB >> 15056378

Activation of human macrophages by allogeneic islets preparations: inhibition by AOP-RANTES and heparinoids.

Séverine Sigrist1, José Oberholzer, Alain Bohbot, Guy Esposito, Karim Mandes, Roger Lamartine, Christian Toso, Pascal Bucher, Michel Pinget, Laurence Kessler.   

Abstract

During transplantation, pancreatic islets release chemokines which promote macrophage attraction, hampering engraftment of islets. The aim of this study was to modulate chemotaxis and the immune response of human macrophages induced by islets. Human monocyte-derived macrophages of healthy subjects were exposed to supernatants of human islets. Chemotaxis, tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) release were evaluated. To modulate migration, human macrophages were incubated in the presence of aminooxypentane-regulated on activation, normal, T-cell expressed, and secreted (AOP-RANTES), a potent antagonist of CCR5. Chemotactic activity of islets supernatant was modulated by the addition of heparin or heparinoids [pentosan and calix[8S]arene (C8S)]. AOP-RANTES significantly reduced, in a dose-dependent manner, macrophage chemotaxis and cytokine release induced by islets supernatant. The chemotactic index was reduced from 3.05 +/- 0.27 to 0.71 +/- 12, TNF-alpha from 1205 +/- 52 to 202 +/- 12 pg/ml, and IL-1beta from 234 +/- 12 to 10 +/- 6 pg/ml. The trapping of chemokines by heparinoids reduced the chemotactic activity of islets supernatant from 3.05 +/- 0.27 to 1.2 +/- 0.1 with heparin or pentosan and to 1.72 +/- 0.22 with C8S, and also decreased the TNF-alpha release by human macrophages from 1205 +/- 35 to 1000 +/- 26 (C8S), 250 +/- 21 (heparin) and 320 +/- 19 (pentosan) pg/ml, and IL-1beta from 234 +/- 13 to 151 +/- 5 (C8S), 50 +/- 3 (heparin) and 57 +/- 4 (pentosan) pg/ml. In conclusion, AOP-RANTES and heparinoids inhibit human macrophage activation and migration induced by islets supernatant.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15056378      PMCID: PMC1782436          DOI: 10.1111/j.1365-2567.2004.01828.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  32 in total

1.  Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment.

Authors:  H J Gröne; C Weber; K S Weber; E F Gröne; T Rabelink; C M Klier; T N Wells; A E Proudfood; D Schlöndorff; P J Nelson
Journal:  FASEB J       Date:  1999-08       Impact factor: 5.191

2.  Murine chemokine gene expression in rejecting pig proislet xenografts.

Authors:  M F Paule; S R McColl; C J Simeonovic
Journal:  Transplant Proc       Date:  2000-08       Impact factor: 1.066

3.  Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.

Authors:  E De Clercq; D Schols
Journal:  Antivir Chem Chemother       Date:  2001

Review 4.  A new insight into the role of "old" chemotactic peptide receptors FPR and FPRL1: down-regulation of chemokine receptors CCR5 and CXCR4.

Authors:  Y Le; W Shen; B Li; W Gong; N M Dunlop; J M Wang
Journal:  Forum (Genova)       Date:  1999 Oct-Dec

5.  CC chemokine receptor 5 and renal-transplant survival.

Authors:  M Fischereder; B Luckow; B Hocher; R P Wüthrich; U Rothenpieler; H Schneeberger; U Panzer; R A Stahl; I A Hauser; K Budde; H Neumayer; B K Krämer; W Land; D Schlöndorff
Journal:  Lancet       Date:  2001-06-02       Impact factor: 79.321

6.  Human islet transplantation network for the treatment of Type I diabetes: first data from the Swiss-French GRAGIL consortium (1999-2000). Groupe de Recherche Rhin Rhĵne Alpes Genève pour la transplantation d'Ilots de Langerhans.

Authors:  P Y Benhamou; J Oberholzer; C Toso; L Kessler; A Penfornis; F Bayle; C Thivolet; X Martin; F Ris; L Badet; C Colin; P Morel
Journal:  Diabetologia       Date:  2001-07       Impact factor: 10.122

7.  Macrophage activation in type 1 diabetic patients with catheter obstruction during peritoneal insulin delivery with an implantable pump.

Authors:  L Kessler; S Tritschler; A Bohbot; S Sigrist; V Karsten; S Boivin; P Dufour; A Belcourt; M Pinget
Journal:  Diabetes Care       Date:  2001-02       Impact factor: 19.112

8.  Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.

Authors:  A M Shapiro; J R Lakey; E A Ryan; G S Korbutt; E Toth; G L Warnock; N M Kneteman; R V Rajotte
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

9.  Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol.

Authors:  E A Ryan; J R Lakey; R V Rajotte; G S Korbutt; T Kin; S Imes; A Rabinovitch; J F Elliott; D Bigam; N M Kneteman; G L Warnock; I Larsen; A M Shapiro
Journal:  Diabetes       Date:  2001-04       Impact factor: 9.461

10.  Beneficial effects of targeting CCR5 in allograft recipients.

Authors:  W Gao; K L Faia; V Csizmadia; S T Smiley; D Soler; J A King; T M Danoff; W W Hancock
Journal:  Transplantation       Date:  2001-10-15       Impact factor: 4.939

View more
  4 in total

1.  Pro-inflammatory and pro-oxidant status of pancreatic islet in vitro is controlled by TLR-4 and HO-1 pathways.

Authors:  Kevin Vivot; Allan Langlois; William Bietiger; Stéphanie Dal; Elodie Seyfritz; Michel Pinget; Nathalie Jeandidier; Elisa Maillard; Jean-Pierre Gies; Séverine Sigrist
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

2.  Inhibition of gelatinase B (matrix metalloprotease-9) activity reduces cellular inflammation and restores function of transplanted pancreatic islets.

Authors:  Neelam Lingwal; Manju Padmasekar; Balaji Samikannu; Reinhard G Bretzel; Klaus T Preissner; Thomas Linn
Journal:  Diabetes       Date:  2012-05-14       Impact factor: 9.461

3.  Alpha-1 antitrypsin suppresses macrophage activation and promotes islet graft survival after intrahepatic islet transplantation.

Authors:  Wenyu Gou; Jingjing Wang; Lili Song; Do-Sung Kim; Wanxing Cui; Charlie Strange; Hongjun Wang
Journal:  Am J Transplant       Date:  2020-11-16       Impact factor: 9.369

4.  Improvement of islet graft function using liraglutide is correlated with its anti-inflammatory properties.

Authors:  A Langlois; S Dal; K Vivot; C Mura; E Seyfritz; W Bietiger; C Dollinger; C Peronet; E Maillard; M Pinget; N Jeandidier; S Sigrist
Journal:  Br J Pharmacol       Date:  2016-11-06       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.